Article

Alfa Chemistry Launches Donepezil for Alzheimer's Disease Research

Topic: Business DevelopmentPublished August 4, 2022

Legacy signals

Legacy popularity: 274 legacy views

Alfa Chemistry, a long-term partner for many pharmaceutical companies, universities, and research institutions, recently announced to offer donepezil, a synthetic active pharmaceutical ingredient (API) that can be used in pharmaceutical preparation for the treatment of Alzheimer's disease. API refers to the biologically active component of a drug product. In recent decades, the great importance of APIs has been increasingly emphasized within the pharmaceutical industry, and vast research has been carried out from every possible angle, trying to maximize the number of effective formulations. "The drug manufacturing sector has expanded dramatically over the past years, hence, the demand for APIs increases accordingly. As a chemical supplier trusted by a large number of customers, we've made the decision to provide a series of high-quality synthetic APIs at the most reasonable prices," said the Marketing Chief of Alfa Chemistry. "Donepezil is the first API we launched. After almost half a year, its sales volume is quite eye-catching. We are very glad that this chemical has been well-received by the market and will continue to step up our efforts in bringing more APIs to both the research community and industry." Alzheimer's disease (AD), the most common type of dementia, is a neurodegenerative disease featuring continuous decline in thinking, behavioral and social skills. Though no curing medication for Alzheimer's is available yet, various possible treatments, drug or non-drug, have been extensively explored in the hope of slowing down the disease progression or relieving related symptoms. Among them, donepezil is of great interest and has been approved in several countries for anti-dementia. Donepezil demonstrated significant therapeutic effects on the treatment of Alzheimer's disease. "With a strong technical platform and professional technicians, we can ensure the safety of API production in line with the quality standards and the continuous improvement of cGMP requirements," the Marketing Chief further added. Please visit https://www.alfa-api.com/products/donepezil.html to learn more.

Further reading

Further Reading

4 total

Article

Artificial intelligence continues to dominate business conversations, but enthusiasm alone does not guarantee results. While many companies rush to adopt AI in hopes of gaining a competitive edge, a large number of initiatives still fall short. The problem is rarely the technology itself. More often, failure happens because organizations approach AI without the structure, readiness, and discipline required for long-term success. AI projects do not fail because the technology

March 4, 2026

Article

AI Avatar Development: Real Innovation or Just Hype? In today’s hyperconnected world, attention is currency. To stand out, brands can no longer settle for flashy features or surface-level engagement. They need to build meaningful, scalable, and personalized experiences. Enter AI avatars: digital humans that are revolutionizing communication by bringing lifelike presence to virtual interactions. Imagine a team member who never takes a coffee break, speaks ten languages fluen

February 27, 2026

Article

The Quiet Engine Behind Every Connection Most people think of telecom services as towers, signals, and mobile data moving invisibly through the air. Yet behind every call that connects and every message that reaches its destination, there is another system quietly working in the background. That system is the call center. While customers often interact with telecom companies only when something goes wrong, these centers operate constantly, guiding problems toward solutions an

February 23, 2026

Article

Introduction The solar industry once believed that collecting as many leads as possible was the fastest path to growth. Marketing teams focused on filling databases with names, phone numbers, and email addresses. At first, the numbers looked promising. Dashboards showed rising interest and more inquiries than ever before. Yet behind the scenes, many companies began to notice a quiet problem. Revenue growth did not match the flood of leads. Sales teams felt overwhelmed, conver

February 6, 2026